Embecta Corp. (NASDAQ:EMBC) Stock Has Average Price Target of $11.00 According to Brokerages

Shares of Embecta Corp. (NASDAQ:EMBC) have received a consensus rating of “Reduce” from the five research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $11.00.

Several brokerages have weighed in on EMBC. Weiss Ratings raised Embecta from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, October 9th. Zacks Research upgraded Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th.

Embecta Price Performance

NASDAQ:EMBC opened at $6.68 on Thursday. The firm has a market capitalization of $378.49 million, a P/E ratio of 4.51 and a beta of 0.84. Embecta has a 1-year low of $2.77 and a 1-year high of $14.91. The company’s fifty day moving average price is $5.55 and its 200-day moving average price is $4.97.

Embecta (NASDAQ:EMBC) last issued its earnings results on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.29. The firm had revenue of $271.70 million during the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The firm’s revenue was down 8.1% compared to the same quarter last year. During the same quarter last year, the company posted $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Equities analysts anticipate that Embecta will post 1.84 EPS for the current fiscal year.

Embecta Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th were paid a $0.01 dividend. The ex-dividend date was Thursday, August 27th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.6%. Embecta’s dividend payout ratio is presently 2.70%.

Insider Buying and Selling

In related news, Director Milton Mayo Morris sold 6,293 shares of Embecta stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $5.88, for a total transaction of $37,002.84. Following the completion of the transaction, the director directly owned 53,828 shares in the company, valued at approximately $316,508.64. This trade represents a 10.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Devdatt Kurdikar purchased 30,000 shares of Embecta stock in a transaction that occurred on Wednesday, August 12th. The shares were bought at an average price of $4.70 per share, with a total value of $141,000.00. Following the completion of the transaction, the chief executive officer owned 804,919 shares of the company’s stock, valued at $3,783,119.30. This represents a 3.87% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 70,000 shares of company stock valued at $334,200 in the last three months. 1.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Embecta

A number of hedge funds and other institutional investors have recently made changes to their positions in EMBC. Quadrant Capital Group LLC purchased a new stake in Embecta during the third quarter worth $62,000. CWA Asset Management Group LLC grew its position in Embecta by 43.4% during the third quarter. CWA Asset Management Group LLC now owns 537,838 shares of the company’s stock valued at $3,044,000 after buying an additional 162,891 shares during the period. GAMMA Investing LLC grew its position in Embecta by 101.5% during the third quarter. GAMMA Investing LLC now owns 10,898 shares of the company’s stock valued at $62,000 after buying an additional 5,490 shares during the period. Krensavage Asset Management LLC increased its holdings in Embecta by 54.4% in the second quarter. Krensavage Asset Management LLC now owns 1,135,340 shares of the company’s stock valued at $3,701,000 after buying an additional 400,000 shares in the last quarter. Finally, Engineers Gate Manager LP increased its holdings in Embecta by 24.9% in the second quarter. Engineers Gate Manager LP now owns 98,935 shares of the company’s stock valued at $323,000 after buying an additional 19,728 shares in the last quarter. Institutional investors and hedge funds own 93.83% of the company’s stock.

About Embecta

Embecta Corporation (NASDAQ: EMBC) is a global diabetes-care company that develops, manufactures and markets medical devices used to deliver insulin and monitor blood glucose. Its product portfolio includes insulin pen needles, insulin syringes, safety-engineered injection devices, lancets and related diabetes-management products.

The company serves people with diabetes, health care professionals, hospitals and other health care providers through commercial operations and distribution partners in markets around the world.